Stada Prepares Billion-Dollar Exchange in Autumn

kreiszeitung.de

Badische Neueste Nachrichten

View article

nn.de

View article

aachener-zeitung.de

View article

onetz.de

View article

op-online.de

View article

mannheim24.de

View article

bbv-net.de

View article

finanzen100.de

View article

+8 Reposted by 8 other sources

Center

Factuality

Ownership

The first attempt failed due to stock market turbulence due to Trump's tariffs, now the pharmaceutical company is taking a new attempt. Stada CEO Goldschmidt relies on a stable environment - and sees an advantage.

Capital.de

Factuality

Ownership

The drug manufacturer Stada is taking a new start for its billion-dollar return to the Frankfurt Stock Exchange. Corporate CEO Goldschmidt is relying on a stable environment - and sees an advantageThe drug manufacturer Stada is taking a new start for a billion-dollar IPO in Frankfurt. "We are preparing an IPO in the autumn, provided the framework conditions are right", said Stada CEO Peter Goldschmidt of the German Press Agency. Unlike in spring…

finance-magazin.de

Factuality

Ownership

The private equity investors Bain Capital and Cinven want to bring Stada to the stock market. The exit has been on the market for more than two years. Stada is now expected to return to the stock market. "We are preparing an IPO in the autumn, provided the conditions are right," explained Stada CEO Peter Goldschmidt to the Deutsche Presse-Agentur. Unlike in the spring, the financial market environment is currently more stable. An official announ…

Kurier

Factuality

Ownership

Would be one of the largest IPOs in Europe this year. Pharmaceutical manufacturers increased sales by 6 percent to EUR 2.12 billion.

manager magazin

Factuality

Ownership

In the spring, Stada canceled its IPO after share prices fluctuated sharply due to Trump's tariff policy. It is now expected to go public in October, and the billion-dollar valuation should earn the pharmaceutical company at least a spot on the MDAX.

epochtimes.de

Factuality

Ownership

The first attempt failed due to stock market turbulence due to Trump's tariffs, now the pharmaceutical company is taking a new attempt. Stada CEO Goldschmidt is relying on a stable environment – and sees an advantage.